Dr. Emre Yekedüz is a medical oncologist and research fellow in medicine at Dana-Farber Cancer Institute in Boston.
June 30, 2025
Video
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
May 27, 2025
A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.
March 25, 2025
Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.
March 18, 2025
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
IV Complications and the Challenge of Being Heard
Save Meds, Save Lives: How to Donate Your Extra Cancer Medication
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Welireg Improves Quality-Adjusted Survival Time in Advanced RCC